Welcome to our dedicated page for Vigil Neuroscience SEC filings (Ticker: VIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a microglia-focused biotech means wading through technical disclosures, from pre-clinical data tables to FDA correspondence buried deep in appendices. Vigil Neuroscience’s SEC documents are no exception—its annual report details R&D expenses tied to TREM2 agonists, while 8-K releases often announce early efficacy readouts. If you have ever searched for “Vigil Neuroscience SEC filings explained simply,” you know how time-consuming it is to locate the exact trial milestone or cash-runway figure.
Stock Titan solves that problem. Our AI scans every “Vigil Neuroscience quarterly earnings report 10-Q filing,” parses scientific terminology and flags what matters: fresh safety signals, phase-transition timelines and dilution risk. Need “Vigil Neuroscience Form 4 insider transactions real-time”? We alert you the moment an executive buys or sells shares, helping you compare confidence levels across development stages. The same engine delivers concise digests of the “Vigil Neuroscience annual report 10-K simplified,” highlights segment spending, and links directly to tables on R&D burn.
All filing types are covered and updated the instant EDGAR posts them: 10-K, 10-Q, 8-K, S-3, SC 13G and the “Vigil Neuroscience proxy statement executive compensation.” Use AI-powered summaries to interpret “Vigil Neuroscience insider trading Form 4 transactions,” evaluate liquidity in seconds with “Vigil Neuroscience earnings report filing analysis,” or quickly review “Vigil Neuroscience 8-K material events explained.” With Stock Titan you are not just downloading PDFs—you are understanding Vigil Neuroscience SEC documents with AI and turning dense neuroscience jargon into actionable insight.
Vigil Neuroscience, Inc. (VIGL) – Form 4 filing (08/05/2025)
Chief Medical Officer Dr. Petra Kaufmann reported the disposition of all outstanding stock options in connection with the closing of the merger between Vigil and Sanofi. At the 08/05/2025 effective time, Sanofi’s wholly-owned subsidiary merged with Vigil, making Vigil a wholly-owned Sanofi unit.
- Cash consideration to shareholders: every Vigil common share was converted into $8.00 in cash plus one contingent value right (CVR) worth up to $2.00 upon a specified clinical milestone.
- Options cancelled & cashed-out: 144,000 options (exercise $2.19) and 330,000 options (exercise $3.14) were cancelled. Holders receive cash equal to the spread versus $8.00 plus one CVR per underlying share.
- Acceleration: all unvested options became fully vested before cancellation.
- Following the transaction, Dr. Kaufmann reports zero derivative securities remaining.
The filing confirms consummation of the Sanofi acquisition and crystallises value for option holders and common shareholders.
Vigil Neuroscience, Inc. (VIGL) – Form 4, filed 08/05/2025
Director Bruce Booth reports the disposition of all directly and indirectly held equity in connection with the closing of VIGL’s merger with Sanofi. On the effective date, each share of VIGL common stock was converted into the right to receive $8.00 in cash plus one contingent value right (CVR) worth up to $2.00 upon achievement of a clinical milestone.
- Common shares disposed: 5,000 RSUs (direct), 4,808,896 shares (Atlas Venture Fund XII, L.P.), 1,027,978 shares (Atlas Venture Opportunity Fund I, L.P.).
- Stock options disposed: 144,446 options with exercise prices between $2.19 – $3.39 were accelerated, cashed out for the cash-merger spread, and exchanged for CVRs.
- All unvested RSUs and options became fully vested immediately prior to closing.
- Post-transaction, the reporting person holds no beneficial ownership of VIGL securities.
The filing confirms that VIGL is now a wholly owned Sanofi subsidiary and that legacy shareholders and option/RSU holders have received the stated merger consideration.
Vigil Neuroscience (VIGL) – Form 4 insider filing
President & CEO Ivana Magovcevic-Liebisch reports the disposition of all directly held equity in connection with the 08/05/2025 closing of Vigil’s merger with Sanofi. At the effective time each outstanding share of common stock converted into the right to receive $8.00 cash plus one contingent value right (CVR) worth up to $2.00, subject to a clinical milestone.
The filing shows 222,687 common shares and eight option grants covering roughly 2.96 million shares marked “D” (disposed). Unvested options were accelerated, then: (i) options with strike < $8 were cashed out for the in-the-money spread and granted one CVR per underlying share; (ii) options with strike ≥ $8 and < $10 were exchanged solely for CVRs, with potential incremental cash if the milestone is achieved. Following these transactions the reporting person lists 0 derivative holdings and retains rights only to the merger consideration.
Vigil Neuroscience, Inc. (VIGL) – Form 4 (Insider Transaction)
Director Gerhard Koenig reported the disposition of all remaining equity interests on 08/05/2025, coinciding with the closing of Vigil’s merger with Sanofi. At the effective time, each outstanding share of Vigil common stock was automatically converted into the right to receive $8.00 in cash plus one contingent value right (CVR) worth up to an additional $2.00, together defined as the “Merger Consideration.”
Koenig’s holdings affected:
- 5,000 restricted stock units (reported as common stock) – cancelled for cash + CVR.
- 110,175 stock options across seven grants (exercise prices $1.89-$6.02) – all vested, cancelled, and cashed out for the intrinsic value difference versus the $8.00 cash price, plus one CVR per underlying share.
Post-transaction, Koenig reports 0 shares and 0 derivative securities, reflecting full exit following Vigil’s transition to a wholly owned Sanofi subsidiary.
FAQ
What is the current stock price of Vigil Neuroscience (VIGL)?
What is the market cap of Vigil Neuroscience (VIGL)?
